-
Product Insights
NewInivata Ltd Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Inivata Ltd Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Inivata Ltd (Inivata), a subsidiary of NeoGenomics Inc, is a cancer genomics company that harnesses liquid biopsy platform to enhance personalized healthcare in oncology. The company’s product portfolio includes InVisionFirst – Lung, which offers advanced sequencing technology to detect copy number variants, single nucleotide variants, insertions and deletions and structural variants in selected genes from DNA isolated from plasma samples...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Niclosamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Niclosamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Niclosamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug...
-
Product Insights
NewArcherDx Inc Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our ArcherDx Inc Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. ArcherDx Inc (ArcherDx) is a molecular technology company that develops customized genomic medicine-based solutions for the discovery of various types of cancer, auto-immune, and other genetic diseases. It offers comprehensive next-generation sequencing (NGS) assays that enable the detection of deoxyribonucleic acid (DNA)-based variant and copy-number variation (CNV); sensitive variant from circulating tumor (ct) DNA; ribonucleic acid (RNA)-based fusion, expression and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BDTX-1535 in High-Grade Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BDTX-1535 in High-Grade Glioma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BDTX-1535 in High-Grade Glioma Drug Details: BDTX-1535 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Diakine-DK210 (EGFR) in Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Diakine-DK210 (EGFR) in Squamous Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Diakine-DK210 (EGFR) in Squamous Cell Carcinoma Drug Details: Diakine-DK210...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Diakine-DK210 (EGFR) in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Diakine-DK210 (EGFR) in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Diakine-DK210 (EGFR) in Colorectal Cancer Drug Details: Diakine-DK210 (EGFR) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Diakine-DK210 (EGFR) in Head And Neck Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Diakine-DK210 (EGFR) in Head And Neck Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Diakine-DK210 (EGFR) in Head And Neck Cancer Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Diakine-DK210 (EGFR) in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Diakine-DK210 (EGFR) in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Diakine-DK210 (EGFR) in Pancreatic Cancer Drug Details: Diakine-DK210 (EGFR) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Diakine-DK210 (EGFR) in Bladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Diakine-DK210 (EGFR) in Bladder Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Diakine-DK210 (EGFR) in Bladder Cancer Drug Details: Diakine-DK210 (EGFR) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Diakine-DK210 (EGFR) in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Diakine-DK210 (EGFR) in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Diakine-DK210 (EGFR) in Solid Tumor Drug Details: Diakine-DK210 (EGFR) is under...